公开(公告)号：US20170197980A1

公开(公告)日：2017-07-13

申请号：US15321153

申请日：2015-06-25

Applicant: AbbVie Inc.

Inventor： Lloyd S. Dias ,  Rodney James Ketner ,  Jonathan M. Miller ,  Warren Kenyon Miller ,  Michael Mark Morgen ,  Brice George Murri ,  David Thomas Vodak

IPC: C07D495/04 ,  C07C309/17

CPC classification number: C07D495/04 ,  C07C309/17

Abstract: Docusate salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.

公开(公告)号：US20150126545A1

公开(公告)日：2015-05-07

申请号：US13704872

申请日：2012-12-14

Applicant: AbbVie Inc.

Inventor： Yi Shi ,  Josh M. Lipari ,  Brian E. Padden ,  Lloyd S. Dias ,  Julie K. Spence

IPC: A61K31/4365 ,  A61K9/00 ,  A61K47/02 ,  A61K47/28 ,  A61K47/10 ,  A61K47/44

CPC classification number: A61K31/4365 ,  A61K9/0019 ,  A61K9/146 ,  A61K47/02 ,  A61K47/10 ,  A61K47/28 ,  A61K47/44

Abstract: A composition comprises a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, in a mixture comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. The composition is suitable for dilution with an IV solution for administration to a subject in need thereof for treatment of a cancer.

Abstract translation: 组合物包含激酶抑制化合物，例如N-（4- {4-氨基-7- [1-（2-羟乙基）-1H-吡唑-4-基]噻吩并[3,2-c]吡啶-3 - 基}苯基）-N' - （3-氟苯基）脲，其包含（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂的混合物。 该组合物适合用IV溶液稀释，用于给予有需要的受试者用于治疗癌症。